Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. Its lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. TTI-0102 has been developed to address the obstacles facing previous thiol-based drugs, their short half-lives and side effects. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism that eliminates the spike in the immediate release of cysteamine that is commonly linked to GI side effects. TTI-0102â€™s initial applications are for mitochondrial encephalopathy, lactic acidosis and stroke-like episodes, Leigh syndrome, Rett syndrome and pediatric Nonalcoholic steatohepatitis.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
17/26/17	CA$0.5700	+7.55%	3,000
16/26/16	CA$0.5300	0.00%	500
15/26/15	CA$0.5300	-7.02%	5,500
14/26/14	CA$0.5700	+1.79%	500

Delayed Quote Toronto S.E.

More quotes

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

Market Closed - Toronto S.E. Other stock markets 01:15:03 18/07/2026 am IST			5-day change	1st Jan Change
0.5700 ^CAD	+7.55%		+1.79%	-12.31%

13/07	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI
13/07	Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation	MT

Market Cap	2.95Cr 2.11Cr 1.84Cr 1.7Cr 1.57Cr 203.1Cr 3.02Cr 20Cr 8Cr 99Cr 7.92Cr 7.75Cr 342.42Cr	P/E 2024	-8.65x	P/E 2025	-4.25x
Enterprise Value	2.79Cr 1.99Cr 1.74Cr 1.61Cr 1.48Cr 191.99Cr 2.86Cr 19Cr 7.56Cr 94Cr 7.49Cr 7.32Cr 323.69Cr	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	87.27%	Yield 2024 *	-	Yield 2025	-

13/07	Thiogenesis Therapeutics Receives Fda Rare Pediatric Disease Designation for Tti-0102 for the Treatment of Leigh Syndrome	CI
13/07	Thiogenesis Therapeutics' Treatment For Leigh Syndrome Receives FDA Rare Pediatric Disease Designation	MT
17/06	Thiogenesis Therapeutics Appoints Gilad Aharon to its Board	MT
17/06	Thiogenesis Therapeutics, Corp. Appoints Gilad Aharon to Its Board of Directors	CI
03/06	Thiogenesis Therapeutics, Corp. announced that it has received CAD 9.07185 million in funding	CI
26/05	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
11/05	Thiogenesis Therapeutics to Raise $8 Million Via a Non-Brokered Private Placement	MT
11/05	Thiogenesis Therapeutics, Corp. announced that it expects to receive CAD 8 million in funding	CI
01/05	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/04	Thiogenesis Therapeutics, Corp. Auditor Raises 'Going Concern' Doubt	CI
02/02	Thiogenesis Therapeutics, Corp. Provides Program Update	CI
23/01	Thiogenesis Therapeutics, Corp. Announces the Presentation of Interim Data from Its Phase 2 (Eu) Clinical Study of Tti-0102 in Patients with Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes At Mitocon 2026	CI
27/11	Thiogenesis Therapeutics, Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

13/07	Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome	NE
17/06	Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors	NE
03/06	Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million	NE
02/06	Thiogenesis Upsizes Non-Brokered Private Placement of Common Shares	NE
11/05	Thiogenesis Announces Non-Brokered Private Placement	NE

Thiogenesis Therapeutics, Corp. Share Price

Stocks

TTI

CA88410L1022

Biotechnology & Medical Research

Valuation: Thiogenesis Therapeutics, Corp.

Chart: Thiogenesis Therapeutics, Corp.

Latest news : Thiogenesis Therapeutics, Corp.

Analysts' recommendations: Thiogenesis Therapeutics, Corp.

Press Releases: Thiogenesis Therapeutics, Corp.

Quotes and Performance

Course Extremes

Managers and Directors: Thiogenesis Therapeutics, Corp.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Net sales - Rate of surprise

1 day	+7.55%
1 week	+1.79%
Current month	+5.56%
1 month	+1.79%
3 months	-6.56%
6 months	-12.31%
Current year	-12.31%

1 week	0.53	0.57
1 month	0.53	0.57
Current year	0.44	0.66
1 year	0.44	0.87
3 years	0.44	1.06
5 years	0.38	1.06
10 years	0.38	1.06

Manager	Title	Age	Since
Patrice Rioux CEO	Chief Executive Officer	75	31/03/2022
Brook Riggins CEO	Chief Executive Officer	60	-

Director	Title	Age	Since
Kim Tsuchimoto BRD	Director/Board Member	63	31/03/2022
Christopher Starr CHM	Chairman	73	31/03/2022
Brook Riggins BRD	Director/Board Member	60	03/05/2018

Date	Insider	Type	Main position	Quantity	% Market Cap.
01/06/26	W. Mullally	Sell	Director	1,50,000	0.2894%
11/09/25	W. Mullally	Option	Director	75,000	0.1702%
01/08/25	W. Mullally	Sell	Director	64,000	0.1453%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THIOGENESIS THERAPEUTICS, CORP.	+7.55%	+1.79%	-27.85%	-13.64%	2.11Cr
LONZA GROUP AG	-1.29%	-3.11%	-0.35%	+3.09%	4.92TCr
REVOLUTION MEDICINES, INC.	+3.90%	-0.39%	+386.06%	+593.85%	3.96TCr
BEONE MEDICINES AG	-1.70%	+4.46%	+5.93%	+60.25%	3.47TCr
IQVIA HOLDINGS INC.	-2.01%	-0.76%	+28.41%	-8.01%	3.44TCr
CELLTRION, INC.	+0.06%	+0.34%	+2.38%	+34.38%	2.71TCr
ASCENDIS PHARMA A/S	+0.46%	-3.49%	-	-	1.62TCr
MEDPACE HOLDINGS, INC.	-0.04%	-0.09%	+72.42%	+115.55%	1.54TCr
EUROFINS SCIENTIFIC SE	+1.12%	+1.91%	+14.54%	+19.16%	1.41TCr
ICON PUBLIC LIMITED COMPANY	0.00%	+1.36%	+18.43%	-30.79%	1.3TCr
Average	+0.80%	+0.20%	+55.55%	+85.98%	2.44TCr
Weighted average by Cap.	-0.05%	-0.18%	+79.43%	+123.30%

	2024	2025
Net sales	-	-
Net income	-31.46L -22.45L -19.62L -18.11L -16.69L -22Cr -32.16L -2.16Cr -85.12L -11Cr -84.32L -82.47L -36Cr	-74.26L -53.01L -46.32L -42.74L -39.4L -51Cr -75.91L -5.11Cr -2.01Cr -25Cr -1.99Cr -1.95Cr -86Cr
Net Debt	-38.48L -27.47L -24L -22.15L -20.42L -26Cr -39.33L -2.65Cr -1.04Cr -13Cr -1.03Cr -1.01Cr -45Cr	-16.16L -11.53L -10.08L -9L -9L -11Cr -16.52L -1.11Cr -43.73L -5.44Cr -43.32L -42.37L -19Cr